XASX
OIL
Market cap127mUSD
Oct 09, Last price
0.16AUD
1D
-8.57%
1Q
3.23%
Jan 2017
166.67%
Name
Optiscan Imaging Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Optiscan Imaging Limited specializes in the development and market introduction of confocal microscopy technology, applied across both clinical and pre-clinical settings in Australia, Germany, and other global regions. A notable offering is the FIVE2 (ViewnVivo) system, a compact confocal endomicroscope utilized for a broad range of research, including clinical, translational, and pre-clinical studies. Additionally, the company is actively developing the InVivage device, which is intended for use in cancer screening and surgical procedures. Established in 1994, Optiscan Imaging Limited maintains its headquarters in Mulgrave, Australia.
Key people
Robert Cooke
Non-Executive Chairman of the Board · since 2021
Camile Farah
Chief Executive Officer, Managing Director, Executive Director · since 2021
Darius Ooi
Chief Financial Officer · since 2025
Brendan Fafiani
Chief Operating Officer · since 2023
Elissa Hansen
Company Secretary · since 2025
Karen Borg
Non-Executive Director · since 2021
Sean Gardiner
Non-Executive Director · since 2022
Ron Song
Non-Executive Director · since 2021
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑06 | 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||